股本结构
单位：万股
| 公告日期 | 2026-08-07 | 2026-08-07 | 2026-06-23 | 2026-05-08 | 2026-05-08 | 2026-03-13 |
|---|---|---|---|---|---|---|
| 证券总股本 | 11150.98 | 10603.38 | 11148.88 | 9702.83 | 9133.71 | 9696.36 |
| 普通股本 | 11150.98 | 10603.38 | 11148.88 | 9702.83 | 9133.71 | 9696.36 |
| 优先股 | 未披露 | 369.72 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2026-08-01 | 2026-06-30 | 2026-05-31 | 2026-05-01 | 2026-03-31 | 2026-03-02 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2026-08-07 | 11150.98 | 未披露 | 定期报告 | 2026-08-01 |
| 2026-08-07 | 10603.38 | 369.72 |
更多>>
From March 31, 2026 to June 30, 2026
Shares issued upon common control merger with Cullgen
Stock options exercised
|
2026-06-30 |
| 2026-06-23 | 11148.88 | 未披露 | 定期报告 | 2026-05-31 |
| 2026-05-08 | 9702.83 | 未披露 | 定期报告 | 2026-05-01 |
| 2026-05-08 | 9133.71 | 未披露 |
更多>>
From December 31,2025 to March 31,2026
Stock options exercised
|
2026-03-31 |
| 2026-03-13 | 9696.36 | 未披露 | 定期报告 | 2026-03-02 |
| 2026-03-13 | 9131.40 | 未披露 |
更多>>
From December 31, 2024 to December 31, 2025
Stock options exercised
Issuance of Common Stock upon ATM program
Issuance of Common Stock
|
2025-12-31 |
| 2025-11-07 | 9633.32 | 未披露 | 定期报告 | 2025-10-31 |
| 2025-11-07 | 9089.04 | 未披露 |
更多>>
From June 30, 2025 to September 30, 2025
Stock options exercised
|
2025-09-30 |
| 2025-08-11 | 9631.32 | 未披露 | 定期报告 | 2025-07-31 |
| 2025-08-11 | 9082.28 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock
Stock options exercised
|
2025-06-30 |
| 2025-05-23 | 9597.98 | 未披露 |
更多>>
Common stock offered 2,222,222 shares by the company
|
2025-05-27 |
| 2025-05-09 | 9375.76 | 未披露 | 定期报告 | 2025-05-01 |
| 2025-04-21 | 9374.26 | 未披露 | 定期报告 | 2025-04-10 |
| 2025-05-09 | 8763.62 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Stock options exercised
Issuance of Common Stock in ATM program
|
2025-03-31 |
| 2025-04-21 | 9361.24 | 未披露 | 定期报告 | 2025-03-12 |
| 2025-03-17 | 8633.22 | 未披露 | 定期报告 | 2025-03-07 |
| 2025-03-17 | 8630.75 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Stock options exercised
Convertible preferred stock conversion
Issuance of Common Stock upon ATM program
|
2024-12-31 |
| 2024-11-13 | 8582.23 | 未披露 | 定期报告 | 2024-11-08 |
| 2024-11-13 | 8576.95 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Stock options exercised
|
2024-09-30 |
| 2024-08-13 | 8560.88 | 未披露 | 定期报告 | 2024-08-06 |
| 2024-08-13 | 8553.78 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Stock options exercised
|
2024-06-30 |
| 2024-05-13 | 8551.01 | 未披露 | 定期报告 | 2024-05-06 |
| 2024-05-30 | 8549.01 | 未披露 | 定期报告 | 2024-05-01 |
| 2024-04-29 | 8546.67 | 未披露 | 定期报告 | 2024-04-18 |
| 2024-05-13 | 8542.32 | 未披露 |
更多>>
From December 31, 2023 to March 31, 2024
Stock options exercised
Convertible preferred stock conversion
|
2024-03-31 |
| 2024-03-27 | 8542.32 | 未披露 | 定期报告 | 2024-03-19 |
| 2024-03-27 | 7659.56 | 1.32 |
更多>>
From December 31, 2022 to December 31, 2023
Stock options exercised
Acquisition of minority interest
Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions
|
2023-12-31 |
| 2023-11-01 | 7658.36 | 未披露 |
更多>>
Effective at 12:01 a.m. Eastern Time on October 30, 2023, Catalyst effected a 1-for-15 reverse stock split of Common Stock (the “Reverse Stock Split”).
|
2023-10-31 |
| 2023-10-26 | 3797.81 | 1.23 |
更多>>
From June 30, 2023 to September 30, 2023
Reclassification of preferred stock to permanent equity
Elimination and redemption of preferred stock
Issuance of common stock from stock grants
|
2023-09-30 |
| 2023-07-20 | 3797.49 | 16.12 | 定期报告 | 2023-07-19 |
| 2023-08-14 | 3797.49 | 5.03 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of preferred stock for stock dividends
|
2023-06-30 |
| 2023-05-15 | 3775.98 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock from stock grants
|
2023-03-31 |
| 2023-03-30 | 3775.98 | 未披露 | 定期报告 | 2023-03-24 |
| 2023-03-30 | 3775.66 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock from stock grants and option exercises
Issuance of common and preferred stock upon acquisition of F351 Assets
Stock-based compensation expense
|
2022-12-31 |
| 2022-11-14 | 3149.01 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock from stock grants and option exercises
|
2022-09-30 |
| 2022-05-09 | 3147.71 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Stock-based compensation expense
Issuance of common stock from stock grants
|
2022-03-31 |
| 2022-03-31 | 3147.71 | 未披露 | 定期报告 | 2022-03-25 |
| 2021-11-12 | 3140.97 | 未披露 | 定期报告 | 2021-11-08 |
| 2021-11-12 | 3139.26 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
|
2021-09-30 |
| 2021-08-05 | 3136.57 | 未披露 | 定期报告 | 2021-07-30 |
| 2021-08-05 | 3134.97 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
|
2021-06-30 |
| 2021-04-27 | 3134.97 | 未披露 | 定期报告 | 2021-04-12 |
| 2021-05-06 | 3133.10 | 未披露 |
更多>>
From December 31, 2020 to February 25, 2021
Stock-based compensation expense
Issuance of common stock for public offering, net of issuance costs of $3,563
Issuance of common stock from stock grants
|
2021-02-25 |
| 2021-01-29 | 3078.29 | 未披露 |
更多>>
1.Common stock offered by the company 8,700,000 Shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 22,082,924 shares of common stock outstanding as of September 30, 2020.
|
2021-01-29 |
| 2021-03-04 | 2209.78 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Stock-based compensation expense
Issuance of common stock from ESPP purchases and stock option exercises
Issuance of common stock for public offering, net of issuance costs of $4,559,000
|
2020-12-31 |
| 2020-11-05 | 2209.78 | 未披露 | 定期报告 | 2020-10-29 |
| 2020-11-05 | 2208.29 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Stock-based compensation expense
Issuance of common stock from stock grants
|
2020-09-30 |
| 2020-08-06 | 2206.30 | 未披露 | 定期报告 | 2020-07-30 |
| 2020-08-06 | 2205.07 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Stock-based compensation expense
Issuance of common stock for public offering, net of issuance costs of $2,045,000
|
2020-06-30 |
| 2020-06-22 | 2203.47 | 未披露 |
更多>>
1.Common stock offered by the company 4,615,384 shares.
2.The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 17,419,313 shares of common stock outstanding as of March 31, 2020
|
2020-06-22 |
| 2020-05-05 | 1743.54 | 未披露 | 定期报告 | 2020-04-22 |
| 2020-05-11 | 1741.93 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
Issuance of common stock for public offering, net of issuance costs of $2,514
|
2020-03-31 |
| 2020-02-18 | 1664.54 | 未披露 |
更多>>
1.Common stock offered by us 4,615,385 shares
2.The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 12,029,992 shares of common stock outstanding as of September 30, 2019
|
2020-02-18 |
| 2020-02-20 | 1207.68 | 未披露 | 定期报告 | 2020-02-07 |
| 2020-02-20 | 1204.08 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
|
2019-12-31 |
| 2019-11-07 | 1204.08 | 未披露 | 定期报告 | 2019-10-25 |
| 2019-11-07 | 1203.00 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Stock-based compensation expense
Issuance of common stock from option exercises
|
2019-09-30 |
| 2019-08-01 | 1201.59 | 未披露 | 定期报告 | 2019-07-26 |
| 2019-08-01 | 1200.85 | 未披露 |
更多>>
from March 31, 2019 to June 30, 2019
Stock-based compensation expense
Issuance of common stock from option exercises
|
2019-06-30 |
| 2019-05-02 | 1198.01 | 未披露 | 定期报告 | 2019-04-22 |
| 2019-05-02 | 1197.41 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Issuance of common stock from stock grants and option exercises
|
2019-03-31 |
| 2019-03-08 | 1197.00 | 未披露 | 定期报告 | 2019-03-04 |
| 2019-03-08 | 1195.45 | 未披露 |
更多>>
from January 1,2018 to December 31,2018
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Issuance of common stock from stock grants and exercise of stock options (1)
Conversion of redeemable convertible notes to common stock
|
2018-12-31 |
| 2018-12-21 | 1194.77 | 未披露 | 定期报告 | 2018-12-20 |
| 2018-08-02 | 1194.27 | 未披露 |
更多>>
from January 1, 2018 to June 30, 2018
Conversion of preferred stock to common stock
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Stock options exercised for common stock
Conversion of redeemable convertible notes to common stock
|
2018-06-30 |
| 2018-05-03 | 1193.52 | 未披露 | 定期报告 | 2018-04-30 |
| 2018-05-03 | 1193.51 | 未披露 |
更多>>
from January 1, 2018 to March 31, 2018
Conversion of preferred stock to common stock
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Stock options exercised for common stock
Conversion of redeemable convertible notes to common stock
|
2018-03-31 |
| 2018-03-19 | 1189.36 | 未披露 | 定期报告 | 2018-03-15 |
| 2018-01-22 | 636.66 | 未披露 | 定期报告 | 2018-01-19 |
| 2018-03-19 | 608.12 | 0.37 |
更多>>
from December 31, 2016 to December 31, 2017
Issuance of convertible preferred stock, common stock and warrants for follow-on offering, net of issuance costs
Conversion of preferred stock to common stock
Issuance of common stock, net of issuance costs
Issuance of common stock for follow-on offering S-3, net of issuance costs
Issuance of common stock upon exercise of warrants
|
2017-12-31 |
| 2017-08-03 | 431.06 | 0.55 |
更多>>
from December 31, 2016 to June 30, 2017
Issuance of convertible preferred stock, common stock and warrants for follow-on offering, net of issuance costs
Conversion of preferred stock to common stock
Issuance of common stock, net of issuance costs
Issuance of common stock upon exercise of warrants
|
2017-06-30 |
| 2017-05-11 | 426.06 | 未披露 | 定期报告 | 2017-05-04 |
| 2017-05-18 | 426.04 | 未披露 | 定期报告 | 2017-04-24 |
| 2017-04-13 | 310.16 | 1.14 | 定期报告 | 2017-04-12 |
| 2017-04-05 | 124.16 | 未披露 | 定期报告 | 2017-04-03 |
| 2017-05-11 | 100.00 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Issuance of common stock, net of issuance costs
On February 10, 2017, Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a reverse stock split of its shares of common stock at a ratio of one-for-fifteen. The reverse stock split will be effective at 5:00 p.m. Eastern Time on February 10, 2017.
|
2017-03-31 |
| 2017-03-08 | 100.00 | 未披露 | 定期报告 | 2017-02-28 |
| 2017-03-08 | 80.18 | 未披露 |
更多>>
from December 31, 2015 to February 13, 2017
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
On February 10, 2017, Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a reverse stock split of its shares of common stock at a ratio of one-for-fifteen. The reverse stock split will be effective at 5:00 p.m. Eastern Time on February 10, 2017.
|
2017-02-13 |
| 2017-01-12 | 1202.63 | 未披露 | 定期报告 | 2017-01-06 |
| 2016-11-03 | 1202.63 | 未披露 | 定期报告 | 2016-10-31 |
| 2016-11-03 | 1193.60 | 未披露 |
更多>>
From December 31, 2015 to September 30, 2016
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
|
2016-09-30 |
| 2016-08-04 | 1183.59 | 未披露 | 定期报告 | 2016-07-29 |
| 2016-08-04 | 1150.36 | 未披露 |
更多>>
from December 31, 2015 to June 30, 2016
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
|
2016-06-30 |
| 2016-05-05 | 1143.01 | 未披露 |
更多>>
From December 31, 2015 to March 31, 2016
Conversion of redeemable convertible notes to common stock
|
2016-03-31 |
| 2016-03-09 | 1143.01 | 未披露 | 定期报告 | 2016-03-01 |
| 2016-03-09 | 1143.01 | 未披露 |
更多>>
from December 31, 2014 to December 31, 2015
Conversion of convertible notes - related parties to Series F convertible preferred stock
Issuance of Series F convertible preferred stock, net of issuance costs of $96
Conversion of preferred stock to common stock in connection with merger
Stock options exercised for cash
Issuance of common stock in connection with reverse merger
Conversion of redeemable convertible notes to common stock
The 7-for-1 reverse stock split of the common stock on August 20, 2015.
|
2015-12-31 |
| 2015-11-05 | 1142.80 | 未披露 | 定期报告 | 2015-10-30 |
| 2015-11-23 | 1141.25 | 未披露 | 定期报告 | 2015-10-26 |
| 2015-07-31 | 3429.23 | 未披露 | 定期报告 | 2015-07-27 |
| 2014-11-06 | 3431.14 | 未披露 | 定期报告 | 2014-10-31 |
| 2014-04-18 | 3378.46 | 未披露 | 定期报告 | 2014-04-16 |
| 2014-03-14 | 3374.39 | 未披露 | 定期报告 | 2014-02-28 |
| 2013-11-06 | 3366.15 | 未披露 | 定期报告 | 2013-10-31 |
| 2013-03-15 | 3361.67 | 未披露 | 定期报告 | 2013-02-28 |
| 2012-08-09 | 3343.05 | 未披露 | 定期报告 | 2012-07-31 |
| 2012-05-09 | 3339.88 | 未披露 | 定期报告 | 2012-04-30 |
| 2012-03-06 | 3339.63 | 未披露 | 定期报告 | 2012-02-29 |
| 2011-11-03 | 3338.34 | 未披露 | 定期报告 | 2011-10-31 |
| 2011-08-09 | 3337.78 | 未披露 | 定期报告 | 2011-07-31 |
| 2011-05-09 | 2906.69 | 未披露 | 定期报告 | 2011-04-29 |
| 2011-03-11 | 2902.15 | 未披露 | 定期报告 | 2011-02-28 |
| 2010-11-05 | 2865.25 | 未披露 | 定期报告 | 2010-10-31 |
| 2010-08-09 | 2861.84 | 未披露 | 定期报告 | 2010-07-31 |
From March 31, 2026 to June 30, 2026
Shares issued upon common control merger with Cullgen
Stock options exercised
From December 31,2025 to March 31,2026
Stock options exercised
From December 31, 2024 to December 31, 2025
Stock options exercised
Issuance of Common Stock upon ATM program
Issuance of Common Stock
From June 30, 2025 to September 30, 2025
Stock options exercised
From March 31, 2025 to June 30, 2025
Issuance of common stock
Stock options exercised
Common stock offered 2,222,222 shares by the company
From December 31, 2024 to March 31, 2025
Stock options exercised
Issuance of Common Stock in ATM program
From December 31, 2023 to December 31, 2024
Stock options exercised
Convertible preferred stock conversion
Issuance of Common Stock upon ATM program
From June 30, 2024 to September 30, 2024
Stock options exercised
From March 31, 2024 to June 30, 2024
Stock options exercised
From December 31, 2023 to March 31, 2024
Stock options exercised
Convertible preferred stock conversion
From December 31, 2022 to December 31, 2023
Stock options exercised
Acquisition of minority interest
Deemed issuance of common stock and Convertible Preferred Stock to former stockholders of Catalyst upon the GNI USA Contributions
Effective at 12:01 a.m. Eastern Time on October 30, 2023, Catalyst effected a 1-for-15 reverse stock split of Common Stock (the “Reverse Stock Split”).
From June 30, 2023 to September 30, 2023
Reclassification of preferred stock to permanent equity
Elimination and redemption of preferred stock
Issuance of common stock from stock grants
From March 31, 2023 to June 30, 2023
Issuance of preferred stock for stock dividends
From December 31, 2022 to March 31, 2023
Issuance of common stock from stock grants
From December 31, 2021 to December 31, 2022
Issuance of common stock from stock grants and option exercises
Issuance of common and preferred stock upon acquisition of F351 Assets
Stock-based compensation expense
From June 30, 2022 to September 30, 2022
Issuance of common stock from stock grants and option exercises
From December 31, 2021 to March 31, 2022
Stock-based compensation expense
Issuance of common stock from stock grants
From June 30, 2021 to September 30, 2021
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
From March 31, 2021 to June 30, 2021
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
From December 31, 2020 to February 25, 2021
Stock-based compensation expense
Issuance of common stock for public offering, net of issuance costs of $3,563
Issuance of common stock from stock grants
1.Common stock offered by the company 8,700,000 Shares.
2.The number of shares of common stock to be outstanding immediately after this offering as shown above is based on 22,082,924 shares of common stock outstanding as of September 30, 2020.
From December 31,2019 to December 31,2020
Stock-based compensation expense
Issuance of common stock from ESPP purchases and stock option exercises
Issuance of common stock for public offering, net of issuance costs of $4,559,000
From June 30, 2020 to September 30, 2020
Stock-based compensation expense
Issuance of common stock from stock grants
From March 31, 2020 to June 30, 2020
Stock-based compensation expense
Issuance of common stock for public offering, net of issuance costs of $2,045,000
1.Common stock offered by the company 4,615,384 shares.
2.The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 17,419,313 shares of common stock outstanding as of March 31, 2020
From December 31, 2019 to March 31, 2020
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
Issuance of common stock for public offering, net of issuance costs of $2,514
1.Common stock offered by us 4,615,385 shares
2.The number of shares of our common stock to be outstanding immediately after this offering as shown above is based on 12,029,992 shares of common stock outstanding as of September 30, 2019
from December 31, 2018 to December 31, 2019
Stock-based compensation expense
Issuance of common stock from stock grants and option exercises
from June 30, 2019 to September 30, 2019
Stock-based compensation expense
Issuance of common stock from option exercises
from March 31, 2019 to June 30, 2019
Stock-based compensation expense
Issuance of common stock from option exercises
from December 31, 2018 to March 31, 2019
Issuance of common stock from stock grants and option exercises
from January 1,2018 to December 31,2018
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Issuance of common stock from stock grants and exercise of stock options (1)
Conversion of redeemable convertible notes to common stock
from January 1, 2018 to June 30, 2018
Conversion of preferred stock to common stock
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Stock options exercised for common stock
Conversion of redeemable convertible notes to common stock
from January 1, 2018 to March 31, 2018
Conversion of preferred stock to common stock
Issuance of common stock for follow-on offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Stock options exercised for common stock
Conversion of redeemable convertible notes to common stock
from December 31, 2016 to December 31, 2017
Issuance of convertible preferred stock, common stock and warrants for follow-on offering, net of issuance costs
Conversion of preferred stock to common stock
Issuance of common stock, net of issuance costs
Issuance of common stock for follow-on offering S-3, net of issuance costs
Issuance of common stock upon exercise of warrants
from December 31, 2016 to June 30, 2017
Issuance of convertible preferred stock, common stock and warrants for follow-on offering, net of issuance costs
Conversion of preferred stock to common stock
Issuance of common stock, net of issuance costs
Issuance of common stock upon exercise of warrants
from December 31, 2016 to March 31, 2017
Issuance of common stock, net of issuance costs
On February 10, 2017, Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a reverse stock split of its shares of common stock at a ratio of one-for-fifteen. The reverse stock split will be effective at 5:00 p.m. Eastern Time on February 10, 2017.
from December 31, 2015 to February 13, 2017
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
On February 10, 2017, Catalyst Biosciences, Inc., a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced a reverse stock split of its shares of common stock at a ratio of one-for-fifteen. The reverse stock split will be effective at 5:00 p.m. Eastern Time on February 10, 2017.
From December 31, 2015 to September 30, 2016
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
from December 31, 2015 to June 30, 2016
Issuance of common stock, net of issuance costs
Conversion of redeemable convertible notes to common stock
From December 31, 2015 to March 31, 2016
Conversion of redeemable convertible notes to common stock
from December 31, 2014 to December 31, 2015
Conversion of convertible notes - related parties to Series F convertible preferred stock
Issuance of Series F convertible preferred stock, net of issuance costs of $96
Conversion of preferred stock to common stock in connection with merger
Stock options exercised for cash
Issuance of common stock in connection with reverse merger
Conversion of redeemable convertible notes to common stock
The 7-for-1 reverse stock split of the common stock on August 20, 2015.